Canada markets closed

Unicycive Therapeutics, Inc. (UNCY)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8800+0.0432 (+5.16%)
At close: 04:00PM EDT
0.8899 +0.01 (+1.13%)
After hours: 06:09PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.8368
Open0.8448
Bid0.8774 x 100
Ask0.9158 x 100
Day's Range0.8418 - 0.9023
52 Week Range0.4700 - 1.8230
Volume187,164
Avg. Volume367,560
Market Cap33.094M
Beta (5Y Monthly)2.71
PE Ratio (TTM)N/A
EPS (TTM)-0.9200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.30
  • GlobeNewswire

    Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress

    – Results from Preclinical Model of Hyperphosphatemia Demonstrate the Relative Potency of OLC Compared to Tenapanor – – Oral UNI-494 Shows Promise in a Preclinical Model as a Potential Candidate for Prevention of Delayed Graft Function Related to Acute Kidney Injury – LOS ALTOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today ann

  • GlobeNewswire

    Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference

    LOS ALTOS, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in a Fireside Chat at the virtual Lytham Partners Spring 2024 Investor Conference on Thursday, May 30, 2024, at 9:30 a.m. ET. A link to the live and archived webcast may be accessed on the Unicyci

  • GlobeNewswire

    Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting

    – OLC Demonstrates Bioequivalence to Lanthanum Carbonate – – Additional Poster Highlights Key Features of OLC as Perceived by Renal Dieticians – LOS ALTOS, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that two posters related to the Company’s lead product candidate, oxylanthanum carbonate (OLC), were presented at the